[Acute mixed lineage leukemia showing resistance to AML and ALL therapy]

Rinsho Ketsueki. 1993 May;34(5):643-8.
[Article in Japanese]

Abstract

A 51-year-old female was who admitted complaining of cough and slight fever and lower limb petechia. The laboratory examinations revealed leukocytosis (49,400/microliters) with blasts (71%) in the peripheral blood. The NCC was 30 x 10(4)/microliters with 84.8% blasts in the bone marrow. Myeloperoxidase staining was positive for 6% of blasts. Auer rods were not seen in some blasts. Thus, acute myeloblastic leukemia (M1) was diagnosed according to FAB classification. In the peripheral blood, 43.3% of blasts expressed CD19, 10.3% of blasts expressed CD20 and 55.6% of blasts expressed CD33 on admission. Though she received two courses of DCMP according to the DCMP-85 protocol, and one combined course of mitoxantrone, etoposide, and Ara-C. The NCC was 20.0 x 10(4)/microliters with 70% blasts in the bone marrow. CD19 was expressed by 72.4% of blasts and 35.0% expressed CD20. The ALL-90 protocol was started, but remission was not achieved. Thus this case was considered to be acute mixed lineage leukemia.

Publication types

  • Case Reports
  • English Abstract

MeSH terms

  • Antigens, CD / analysis*
  • Antigens, CD19
  • Antigens, Differentiation, B-Lymphocyte / analysis*
  • Antigens, Differentiation, Myelomonocytic / analysis*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • B-Lymphocytes / immunology*
  • Drug Resistance
  • Female
  • Humans
  • Leukemia, Myeloid, Acute / drug therapy*
  • Middle Aged
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
  • Sialic Acid Binding Ig-like Lectin 3

Substances

  • Antigens, CD
  • Antigens, CD19
  • Antigens, Differentiation, B-Lymphocyte
  • Antigens, Differentiation, Myelomonocytic
  • CD33 protein, human
  • Sialic Acid Binding Ig-like Lectin 3